Semax, a synthetic neuroprotective peptide, was tested for its ability to interfere with the process that leads to Alzheimer's-related protein clumping. The study found that Semax binds to copper ions — which normally accelerate the formation of toxic amyloid-beta aggregates — and in doing so, inhibits fiber formation and protects cells. These effects were strongest in the presence of copper, pointing to Semax as a potential multi-target candidate for Alzheimer's drug development.
Sciacca, Michele F M; Naletova, Irina; Giuffrida, Maria Laura; Attanasio, Francesco